Jack Andraka’s Paper Cancer Sensor: The 2012 Promise and What Followed

A research achievement with a specific scope

Andraka’s project was a notable science-fair achievement. In a 2013 interview published by Society for Science, he described developing a paper-based sensor using carbon nanotubes and antibodies to the protein mesothelin. The interview records his account of the work and its claimed performance; it is not itself a clinical validation study.

That distinction preserves the genuine accomplishment. Developing a sensor with research mentorship is demanding work. It does not need to be described as a teenager having already solved cancer diagnosis in order to be worth celebrating.

Three questions between a sensor and a screening program

Can the assay detect the target? This concerns the measurement itself: what substance is detected, under what conditions, and with what reproducibility. A low detectable concentration is an analytical property.

Can the result distinguish the relevant patients? Clinical performance concerns people with and without the condition in the population being tested. Detecting a biomarker and correctly classifying a person are related questions, but they are not identical.

Does using the test improve outcomes? Screening concerns people without symptoms. The National Cancer Institute’s screening overview explains screening as a distinct area of evidence, including whether tests help reduce cancer deaths. A faster laboratory measurement does not, by itself, answer that outcome question.

Cost comparisons need the same clarity. The price of materials for a test strip is different from the full cost of collecting samples, running a service, and investigating results. The dramatic ratios quoted in the 2014 article should therefore remain attached to the student project’s claimed comparison, rather than being presented as a current clinical guarantee.

This is an encouraging story about what curiosity, persistence, and access to a laboratory can make possible. Its next scientific question is validation, not whether enthusiasm can substitute for it.

What happened to the test

The sensor used filter paper coated with single-walled carbon nanotubes and antibodies to the protein mesothelin, and the project claimed it was faster, cheaper and more sensitive than the standard ELISA laboratory test. It drew criticism once the publicity peaked: Ira Pastan, the scientist who discovered mesothelin, said the method “makes no scientific sense”; Harvard geneticist George Church questioned the cost, speed and sensitivity claims; similar carbon-nanotube sensors had been reported in 2005, 2008 and 2009; and Forbes editor Matthew Herper kept Andraka off a “30 Under 30” list because the work had not been published in a peer-reviewed journal. An international patent application filed in 2012 drew a preliminary finding of “lack of inventive step”, and no screening product followed. (Herper set out his reasons in Forbes, 8 January 2014: the work had not been published, writing that “it is by published work that scientists are judged”; expert reviewers including George Church doubted the claimed gains in speed, cost and sensitivity over ELISA; and the sensor had not been tested on human blood samples. The international patent application, “Sensors for detection of mesothelin”, names Andraka as inventor and was filed on 7 December 2012 (WO2013172866, Google Patents).)

Andraka went on to study at Stanford University from 2015, majoring in anthropology and electrical engineering, and won a Truman Scholarship in 2018 (one of 59 students chosen nationally that year (Stanford Report, 13 April 2018)). His story remains a genuine example of a teenager doing serious laboratory work with expert mentoring; the cancer test it promised has not materialised, which is the usual fate of early biomarker ideas rather than evidence of suppression.

For another laboratory advance that requires a distinction from clinical treatment, explore 3D-Printed Corneas: What Newcastle’s 2018 Research Demonstrated.